SARA NIEGO: Open Payments
NPI 1730193814 · HARTFORD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,979 in 213 payments from 22 companies in 2025. Trend: 2023 $4,927 · 2024 $4,479 · 2025 $3,979
Food & beverage: $3,979
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $477 |
| Otsuka America Pharmaceutical, Inc. | 22 | $452 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $451 |
| Vanda Pharmaceuticals Inc. | 18 | $321 |
| E.R. Squibb & Sons, L.L.C. | 29 | $308 |
| Corium, LLC | 17 | $307 |
| Neurocrine BioSciences, Inc. | 9 | $274 |
| Teva Pharmaceuticals USA, Inc. | 13 | $192 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $177 |
| Indivior Inc. | 8 | $162 |
Products named: CAPLYTA, VRAYLAR, REXULTI, FANAPT, COBENFY, Azstarys, INGREZZA, UZEDY.
Industry payments across CT — which companies pay providers there.
